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Abstract
Introduction Drotrecogin alfa (activated) (DrotAA) is licensed in
the United States and the European Union for the treatment of
severe sepsis with multiple organ failure. Patients with severe
sepsis on renal replacement therapy (RRT), who typically
receive additional anticoagulation to prevent circuit clotting, may
be at higher risk of bleeding when DrotAA is administered in
addition to standard anticoagulation. However, the effects of
DrotAA on filter duration in the absence of additional
anticoagulation have not been established. The aim of this study
was to analyse the filter survival time (FST), and to quantify the
requirement of packed red cells (PRC) and blood products
during DrotAA infusion.
Methods This was a single-centre, retrospective observational
study conducted in an adult intensive care unit (ICU). Thirty-five
patients with severe sepsis who had received both RRT and
DrotAA were identified, and all relevant clinical and laboratory
data were retrieved from the departmental electronic patient
record. We compared haemofilter parameters, requirement of
blood products and haemodynamic data recorded during RRT
and the infusion of DrotAA with those recorded on RRT with
standard anticoagulation after the DrotAA infusion had been
completed (post-DrotAA).
Results The proportion of filter changes due to filter clotting
was similar during DrotAA infusion and with conventional
anticoagulation post-DrotAA infusion. There was no difference
in the FST and filter parameters during DrotAA in the presence
or absence of additional anticoagulation with heparin or
epoprostenol. A similar proportion of patients required red cell
transfusion, although a greater proportion of patients received
platelet and fresh frozen plasma during DrotAA infusion
compared with the post-DrotAA period with no difference
between medical and surgical patients.
Conclusions Additional anticoagulation during DrotAA infusion
does not appear to improve FST. The use of DrotAA in patients
with severe sepsis requiring RRT is safe and is not associated
with an increased need for PRC transfusion or major bleeding
events.
Introduction
Drotrecogin alfa (activated) (DrotAA; Xigris, Eli Lilly & Co., Indi-
anapolis, USA), a recombinant human activated protein C, can
reduce mortality in patients with severe sepsis [1]. Data from
long-term follow-up studies [2] and from international and
national registries have also confirmed that the effects of
DrotAA on survival seen in clinical practice are consistent with
those seen in randomised trials [1,3-8]. However, despite the
beneficial outcome data and acceptable safety profile, inten-
sivists are often reluctant to prescribe DrotAA in certain
groups of patients (e.g., patients who have undergone surgery,
patients with coagulopathy or those who receive anticoagu-
lants) because the anticoagulant properties of DrotAA might
increase the risk of bleeding, particularly in the presence of
clotting abnormalities associated with sepsis.
APTT: activated partial thromboplastin time; DrotAA: Drotrecogin alfa (activated); FST: filter survival time; ICU: intensive care unit; INR: international 
normalized ratio; IQR: interquartile range; PRC: packed red cells; RRT: renal replacement therapy.Critical Care    Vol 12 No 6    Camporota et al.
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Anticoagulants are generally given to patients requiring renal
replacement therapy (RRT) to prolong the duration of the filter
and to prevent damage and loss of platelets and erythrocytes
in the clotted circuit. However, the risk of bleeding and the
lifespan of the RRT circuit in patients who continue anticoag-
ulation while receiving DrotAA compared with patients who
receive DrotAA alone is not known. Therefore, the two main
issues concerning the use of DrotAA during RRT are: the
safety of DrotAA in renal failure requiring RRT; and the need
for additional anticoagulation to preserve filter function and
prolong filter survival.
Pharmacokinetic data demonstrate that DrotAA is not elimi-
nated by haemofiltration or dialysis, and its serum concentra-
tion and drug half-life are similar in patients with or without
renal failure; therefore, no dose adjustment is required [9].
However, no specific data are available on the safety of
DrotAA, duration of the RRT circuit survival, bleeding events
leading to red cell transfusion or blood products for the correc-
tion of clotting abnormalities during RRT in septic patients
who receive DrotAA.
The aims of our study were: to analyse the filter survival time
(FST) during DrotAA infusion – in the presence or absence of
additional anticoagulation compared with the 96 hours post-
DrotAA infusion – with standard anticoagulation, while still on
RRT; and to quantify the use of packed red cell (PRC) and
blood products in patients with acute kidney injury requiring
RRT treated with DrotAA.
Materials and methods
Patients
This was a retrospective, single-centre study of patients with
severe sepsis admitted to the adult intensive care unit (ICU) at
St Thomas' Hospital in London, UK. We included all patients
who received DrotAA for severe sepsis with two or more
organs in failure and with acute kidney injury requiring RRT
between 2002 and 2006. The selection of patients eligible for
DrotAA was made in accordance to local protocols and guide-
lines [see Additional data file 1]. In order to achieve the aims
of the study, we specifically selected patients who received a
full course of DrotAA and a minimum of eight days of RRT.
Patients' demographic information, markers of disease sever-
ity, biochemical and haematological data, details of anticoagu-
lation and RRT – including filter pressure parameters – and
quantity and timing of blood products transfused were
obtained by searching the departmental electronic patient
record (CareVue Classic, Philips Medical Systems, Böblingen,
Germany). The modality of RRT used was continuous venous-
venous haemofiltration.
The aim of the study was to compare the proportion of filter
changes secondary to circuit clotting, the FST and the red
cells and blood product transfusion in the same patients dur-
ing the infusion of DrotAA and post-DrotAA, provided they
remained on RRT.
A further comparison of the outcome parameters was made
during the DrotAA infusion period between patients who
received DrotAA without any additional anticoagulation, and
patients who received DrotAA with additional anticoagulation
– heparin or epoprostenol. This study was considered by the
National Research Ethics Service as 'service evaluation' and
therefore did not require Research Ethics Committee review
[10].
Statistical analysis
Distribution of baseline variables was assessed using the Kol-
mogorov-Smirnov test. Differences in baseline variables
between survivors and non-survivors were compared using a
two-tailed t-test or Mann-Whitney U test for continuous data,
and chi-squared or Fisher's exact test for qualitative data. The
Kruskall-Wallis test was used for multiple comparisons.
Variables found to be associated with filter survival in an anal-
ysis of covariance were entered in a multivariate logistic back-
ward-likelihood ratio regression analysis, to identify predictors
of mortality at different end-points. The Hosmer and Lemen-
show goodness-of-fit test was used to test the validity of the
model. Analyses were performed using SigmaStat software v.
3.0 (Systat Software Inc, San Jose, CA, USA).
Results
Patients' characteristics are shown in Table 1.
Effects of DrotAA on filter survival during renal 
replacement therapy in severe sepsis
During the entire study period, there were a total of 145 filter
episodes, with a median (interquartile range (IQR)) = four
(three to five) filter-episode per patient. During RRT DrotAA
was temporarily interrupted in 8 of 35 (22.8%) patients in
order to perform medical procedures (central venous catheter
insertion/removal, n = 4; tracheostomy n = 1; removal of an
intra-aortic balloon pump n = 3).
Although the median (IQR) number of filter episodes per
patient was higher during the DrotAA infusion (89 during
DrotAA; for 35 patients; average 2.5 filter episode per patient)
compared with the post DrotAA period (56 post-DrotAA; for
24 patients; average 2.3 filter episode per patient) (median
(IQR) = three (two to three) versus two (one to three), respec-
tively; p = 0.01), the proportion of filters replaced because of
a clotted circuit was similar during and after DrotAA infusion
(35 of 89 (39.3%) during DrotAA versus 20 of 56 (35.7%)
post-DrotAA) (Table 2). The majority of filter changes (60.7%
during DrotAA and 63.6% post-DrotAA) occurred because of
interruptions in RRT required to perform medical or surgical
procedures, or radiological investigations – rather than filter
clotting.Available online http://ccforum.com/content/12/6/R163
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The lifespan of the circuits changed because of a clotted filter
was longer during DrotAA compared with the FST in the post-
DrotAA (median (IQR) = 22 (15 to 34) hours versus 16 (8 to
26) hours); however, this difference was not statistically signif-
icant (p = 0.08), (Table 2). The median (IQR) filter life span for
clotted versus non-clotted filters was 23.5 (11 to 37) hours
and 22 (15 to 34) hours (p = 0.6) during DrotAA infusion and
16 (8 to 26) hours versus 13 (7 to 43) hours (p = 0.8) post-
DrotAA, respectively. Comparisons of the other filter parame-
ters during the 96-hour DrotAA infusion, and in the 96 hours
post-DrotAA are shown in Table 3.
The median (IQR) FST during DrotAA infusion was not signif-
icantly different between patients receiving DrotAA alone (27
filter episodes; 23 (15 to 35) hours), DrotAA and heparin (13
filter episodes; 21 (14 to 37) hours), DrotAA and epoprostenol
(46 filter episodes; 23 (15 to 35) hours) or DrotAA with
heparin and epoprostenol (3 filter episodes; 34 (11 to 36)
hours) (p = 0.94, Kruskall-Wallis). There was also no differ-
ence in the FST between circuits anticoagulated with DrotAA
alone versus all circuits anticoagulated with DrotAA plus other
forms of anticoagulation (23.5 (11 to 35) hours) and (23 (11
to 35) hours; p = 0.7).
There was no difference in the values of the filter pressure
parameters during DrotAA therapy and in the 96 hours post-
DrotAA. The influence of clotting parameters on FST was also
examined. There was no difference in the platelet count during
DrotAA and post-DrotAA. There was, however, a significant
difference in the maximum value of international normalized
ratio (INR) (p = 0.047) and in the activated partial thrombo-
plastin time (APTT) (p < 0.0001). Multivariate logistic regres-
sion analysis of the factors associated with filter clotting
showed that the administration of other anticoagulants in addi-
tion to DrotAA and the levels of INR and APTT were not asso-
ciated with filter clotting. The only predictive factor
Table 1
Baseline characteristics of study population
Overall population
N3 5
Age, years 65 ± 15
Male/Female 23/12
SOFA 13 ± 2.5
Organ dysfunction, n 4 ± 0.8
APACHE II 23 ± 5
ICU mortality, n (%) 14 (40)
Hospital mortality, n (%) 16 (45.7)
Patients with previous renal impairment* 11 (31%)
Medical, n (%) 15 (43%)
Surgical, n (%) 20 (57%)
Urea, mmol/L 13.5 ± 9.7
Creatinine, mol/L 198.1 ± 108.4
Data are expressed as absolute number (n), percentage or mean ± 
SD.
* Impaired renal function was defined as patients receiving chronic 
dialysis or with documented elevated creatinine prior to current 
illness.
APACHE = Acute Physiology and Chronic Health Evaluation, ICU = 
intensive care unit, SOFA = Sequential Organ Failure Assessment.
Table 2
Filter data
Total filter episodes (n) 145
Total filters/patient median (range) 4 (1 to 8)
Filters/patient on DrotAA median (range) 3 (1 to 4)
Filters/patient post-DrotAA median (range) 2 (1 to 4)
Variable DrotAA Post-DrotAA
Filter changes due to clotting 39.3% 36.4%
FST (hours) 22 (15 to 34) 16 (8 to 26)
Filters anticoagulated with heparin* 13 22
Filters anticoagulated with epoprostenol* 46 25
Filters anticoagulated with heparin and epoprostenol* 3 3
Filters with no additional anticoagulation* 27 6
Filter changes per patients and total filter episodes are expressed as absolute number. Filter survival time (FST) is expressed as median hours 
(interquartile range). * For all filter episodes, patients received drotrecogin alfa (activated) (DrotAA) in addition to the indicated anticoagulation 
during the DrotAA period. When no additional anticoagulation was administered filters were anticoagulated with DrotAA alone during DrotAA 
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significantly, but weakly, associated with filter clotting during
DrotAA, but not post-DrotAA, was the minimum value in plate-
let count: odds ratio = 1.007 (1.001 to 1.01); p = 0.002.
Blood products requirement in patients treated with 
DrotAA
Differences in the haematological parameters during and after
DrotAA are shown in Table 4. There was no difference in the
proportion of patients requiring PRC transfusion during
DrotAA infusion compared with the post-DrotAA period, on
heparin (59% versus 50%; p = 0.8, Fisher's test). Although 3
of 35 (8.6%) patients required PRC transfusion of more than
three units (median (IQR) 1375 (1357 to 1407) mL) during
DrotAA infusion and none post-DrotAA, there was no statisti-
cal difference in the median (IQR) of PRC transfused (549
(292 to 747) mL versus 400 (269 to 565) mL; p = 0.4; Table
5). Of the patients requiring PRC transfusion, 39% had medi-
cal treatment (61% had surgical treatment), but there was also
no difference in the PRC transfusion requirements during
DrotAA between medical and surgical patients (860 (548 to
928) mL versus 747 (450 to 1117) mL; p = 0.86). Similarly
there was no difference in the minimum value of haemoglobin
during DrotAA and in the post-DrotAA period (Table 4).
A larger proportion of patients required platelet transfusion
during DrotAA infusion compared with post-DrotAA on
heparin (38.4% versus 14.2%; p = 0.2, Fisher's test), with a
median (IQR) volume of platelets transfused during DrotAA of
507 (313 to 597) mL compared with the post-DrotAA period
of 290 (285 to 295) mL (p = 0.15), (Table 5). Similarly, there
was a difference in the number of patients receiving fresh fro-
zen plasma during DrotAA (17% versus 8%), with a median
(IQR) of fresh frozen plasma transfused of 1566 (574 to
1884) mL versus 819 (807 to 955) mL in the post-DrotAA
period (Table 5). Transfusion of fresh frozen plasma was asso-
ciated with higher INR levels of 1.43 (1.3 to 1.7) during
DrotAA versus 1.30 (1.2 to 1.8) during the post-DrotAA period
(p = 0.047) and a more prolonged APTT of 56.9 (48.6 to 69.2)
Table 3
Filter parameters
Variable DrotAA median (IQR) Post-DrotAA median (IQR) p-value
PFPMax (mmHg) 208 (142.7 to 247.7) 202 (147 to 258) 0.7
PFPMin (mmHg) 127 (91 to 169.5) 116 (76 to 161) 0.33
TMPMax (mmHg) 114 (88.7 to 151) 106 (79 to 154) 0.37
TMPMin (mmHg) 72 (45 to 101) 60 (48.5 to 73) 0.12
RPMax (mmHg) 155 (100.7 to 196) 140 (110 to 167) 0.21
RPMin (mmHg) 110(70.7 to 141) 94.5 (64 to 123.5) 0.05
Data are expressed as maximum and minimum median values (Interquartile range).
DrotAA = drotrecogin alfa (activated), PFP = pre-filter pressure, TMP = trans-membrane pressure, RP = return pressure.
Table 4
Clotting and haematological parameters during and post-DrotAA infusion
Variable DrotAA median (IQR) Post-DrotAA Median (IQR) p-value
HbMax (g/dL) 10.1 (9.57 to 11.0) 9.45 (8.9 to 10.3) < 0.01*
HbMin, (g/dL) 8.7 (8.1 to 9.3) 8.3 (7.4 to 9.1) 0.1
PLTMax, 104 (64 to 177) 110 (85 to 166) 0.8
PLTMin 88 (41 to 164) 99 (60 to 160) 0.8
FibrinogenMax 5.1 (3.8 to 6.7) 4.4 (3.1 to 6.0) 0.07
FibrinogenMin 4.85 (3.4 to 6.1) 4.4 (3.2 to 6.0) 0.3
INRMax 1.43 (1.3 to 1.7) 1.3 (1.2 to 1.8) 0.047*
INRMin 1.3 (1.2 to 1.5) 1.3 (1.1 to 1.6) 0.8
APTTMax, s 57 (48.6 to 69.2) 43.8 (37 to 62) < 0.01*
APTTMin, s 51 (43.2 to 59) 44 (37 to 62) 0.05
Data are expressed as maximum and minimum median values (interquartile range).
APTT = activated partial thromboplastin time; DrotAA = drotrecogin alfa (activated), Hb = haemoglobin, INR = international normalized ratio; PLT 
= platelets.Available online http://ccforum.com/content/12/6/R163
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seconds during DrotAA versus 43.8 (37 to 69.9) seconds dur-
ing the post-DrotAA period (p < 0.01; Table 4).
Discussion
In 2002, when DrotAA was licensed, no strict protocols or
guidelines were available in the literature on how to manage
RRT in patients receiving DrotAA. In our institution, clinicians
made decisions about anticoagulation in these patients
according to experience and after taking into account the
platelet count, clotting times and filter parameters. This is
reflected in the variety of anticoagulation regimens used in our
dataset.
Our data suggest that additional anticoagulation during
DrotAA infusion does not improve filter survival time. Also, the
lifespan of the circuit during DrotAA is similar to that seen in
the presence or absence of additional anticoagulation while on
DrotAA and with standard anticoagulation in the 96 hours
immediately after DrotAA therapy. Therefore, there is probably
no need for routine additional anticoagulation to preserve cir-
cuit function and this became our practice after 2006.
The data also suggest that the use of DrotAA in patients with
severe sepsis requiring RRT appears safe and is not associ-
ated with an increased need for PRC transfusion or important
bleeding events.
During the DrotAA infusion, there was a greater, albeit not sta-
tistically significant, volume of platelets and fresh frozen
plasma transfused compared with the post-DrotAA period. It is
difficult to understand whether this difference can be entirely
attributed to DrotAA, or whether it is multi-factorial. Other pos-
sible explanations include variable thresholds among clinicians
to correct the commonly observed increased clotting times
induced by DrotAA, or attempts to correct a bleeding event or
a sepsis-induced coagulopathy.
There is minimal data on how to manage anticoagulation in
patients on RRT during the infusion DrotAA therapy and in clin-
ical practice the choice of RRT modalities and anticoagulation
is dependent on expert opinion, and the clinician's level of
experience with both treatments. Our data shows that DrotAA
is as effective as heparin in terms of FST, and these data are
in accordance with a previous report on three patients receiv-
ing DrotAA while on RRT [11]. Several small studies have also
confirmed that in patients at high risk of bleeding and with
some degree of coagulopathy, RRT in the absence of antico-
agulation does not result in a shorter circuit survival time
[12,13]. Furthermore, the presence of sepsis-induced coagu-
lopathy and the effects of DrotAA on the APTT make the mon-
itoring of anticoagulation unreliable and can increase the risk
of inappropriate anticoagulation. Knowledge of the effect of
DrotAA on FST is also important in the presence of thrombo-
cytopenia, which may caution the concomitant use of heparin.
Anticoagulation can be recommenced, as per standard prac-
tice, when the infusion of DrotAA has been completed [9].
In this study we found that our FSTs were generally short (less
than 24 hours). This duration was not solely attributable to fil-
ter clotting, but it was often (60.7% of circuit changes during
DrotAA and 63.6% post-DrotAA) due to investigations (e.g.,
computed tomography scan) or a surgical procedure.
Although our study shows that no additional anticoagulation is
necessary for filter survival, it is now probably advisable to con-
tinue treatment with prophylactic heparin in all patients who
were already receiving it before RRT, as suggested by the
Xigris and PRophylactic hEparin in Severe Sepsis (XPRESS)
study [14,15]. The decision to use heparin should be taken
independently from the decision to use DrotAA and should
take into consideration the bleeding risk of each individual
patient.
Our study has the limitation of being a retrospective analysis in
a small number of patients; however, this is an area of practice
that is clinically important and in which it is difficult for individ-
ual clinicians working in smaller centres to gain sufficient expe-
rience. Another potential confounder is that during the two
periods of time the patients are clearly at different stages of
evolution of the sepsis episode. One therefore might expect
different patterns of coagulation activity between the two
groups. Even so, given these important caveats, it is valuable
to be able to show that anticoagulation for RRT can be carried
out safely with DrotAA alone and that additional anticoagula-
tion is not routinely necessary.
Table 5
Blood product transfusion during and post-DrotAA infusion
Variable DrotAA median (IQR) Post-DrotAA median (IQR) p-value
PRC transfused, mL 549 (292 to 747) 400 (269 to 565) 0.4
Platelets transfused, mL 507 (313 to 597) 290 (285 to 295) 0.15
FFP transfused, mL 1566 (574 to 1884) 819 (807 to 955) 0.35
Data are expressed as median values (interquartile range).
DrotAA = drotrecogin alfa (activated), FFP = fresh frozen plasmam PRC= packed red cell.Critical Care    Vol 12 No 6    Camporota et al.
Page 6 of 6
(page number not for citation purposes)
Conclusion
Additional anticoagulation in patients receiving RRT during
DrotAA infusion is not routinely necessary and does not
improve FST. The use of DrotAA in patients with severe sepsis
requiring RRT is safe and is not associated with an increased
need for PRC transfusion. Interpretation of the effects of
DrotAA on platelet and fresh frozen plasma transfusion are
confounded by the presence of sepsis-induced coagulopathy.
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Key messages
￿  Additional anticoagulation in patients receiving RRT 
during DrotAA infusion is not routinely necessary and 
does not improve FST.
￿  The use of DrotAA in patients with severe sepsis requir-
ing RRT is safe and is not associated with an increased 
need for PRC transfusion.
￿  Interpretation of the effects of DrotAA on platelet and 
fresh frozen plasma transfusion requirements are con-
founded by the presence sepsis-induced coagulopathy.
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